ACAD Shares Outstanding History
Below is a table of the ACAD shares outstanding history going back to 3/1/2010:

Date ACAD Shares Outstanding
3/1/201038.33M
4/30/201038.34M
7/31/201038.37M
10/29/201039.30M
3/1/201151.92M
4/30/201152.71M
7/31/201152.80M
10/31/201152.80M
3/1/201252.90M
4/30/201252.93M
7/31/201253.03M
10/31/201256.62M
3/1/201378.76M
4/29/201379.16M
7/31/201388.78M
10/31/201390.87M
1/31/201491.35M
4/30/201498.98M
7/31/201499.44M
10/31/201499.77M
1/30/2015100.17M
4/30/2015100.30M
7/31/2015100.71M
10/30/2015100.91M
1/29/2016112.64M
4/28/2016113.16M
7/29/2016114.01M
10/31/2016121.11M
1/31/2017121.41M
5/3/2017122.05M
7/31/2017122.40M
10/31/2017124.21M
1/31/2018124.70M
4/30/2018124.83M
7/31/2018125.01M
10/31/2018125.07M

Also see: ACAD Market Cap History
and ACAD YTD Return
ACAD Historical Shares Outstanding:
+14.61% CAGR
ACAD Historical Shares Outstanding: +14.61% CAGR

Mouse over chart for data details
3/1/2010 ...10/31/2018
Acadia Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders. Co.'s portfolio of products includes its drug, NUPLAZID (pimavanserin), which has been approved by the U.S. Food and Drug Administration for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist preferentially targeting 5-HT2A receptors. In addition to PD Psychosis, Co.'s pipeline includes multiple product opportunities being explored in clinical development across several CNS disorders. We show 36 historical shares outstanding datapoints in our coverage of ACAD's shares outstanding history.

Understanding the changing numbers of ACAD shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like ACAD versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching ACAD by allowing them to research ACAD shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes
Get Free SEC filing alerts for ACAD:
ACAD SEC Filing Email Alerts ServiceExternal link
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Acadia Pharmaceuticals (ACAD) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

ACER Shares Outstanding History
ACET Shares Outstanding History
ACHC Shares Outstanding History
ACHN Shares Outstanding History
ACHV Shares Outstanding History
ACOR Shares Outstanding History
ACRS Shares Outstanding History
ACRX Shares Outstanding History
ACST Shares Outstanding History
ADMA Shares Outstanding History
More Healthcare companies »

 

ACAD Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2018, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.